QNTM
HEALTHCAREFSD Pharma Inc - Class B - Class B (Sub Voting)
$5.28-0.08 (-1.49%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving QNTM Today?
No stock-specific AI insight has been generated for QNTM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.07$38.25
$5.28
Fundamentals
Market Cap$31M
P/E Ratio—
EPS$-8.20
Dividend Yield—
Dividend / Share—
ROE-3.5%
Profit Margin—
Debt / Equity—
Trading
Volume208K
Avg Volume (10D)—
Shares Outstanding5.8M
QNTM News
21 articles- Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026Yahoo Finance·May 7, 2026
- Quantum BioPharma Provides Corporate UpdateGlobeNewswire Inc.·Apr 27, 2026
- Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism AccelerantYahoo Finance·Apr 22, 2026
- Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is DeniedYahoo Finance·Apr 2, 2026
- Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple SclerosisYahoo Finance·Apr 1, 2026
- Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple SclerosisYahoo Finance·Mar 30, 2026
- Quantum Biopharma Provides Corporate UpdateGlobeNewswire Inc.·Mar 27, 2026
- Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ StatusYahoo Finance·Mar 27, 2026
- Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple SclerosisYahoo Finance·Mar 26, 2026
- Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With UnbuzzdYahoo Finance·Mar 23, 2026
- Quantum Biopharma Announces Closing of Initial Tranche of Private Placement OfferingYahoo Finance·Mar 20, 2026
- Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)Yahoo Finance·Dec 23, 2025
- World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma SharesYahoo Finance·Dec 22, 2025
- Quantum BioPharma Announces Closing of Private Placement & Provides Corporate UpdateYahoo Finance·Dec 11, 2025
- Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBCYahoo Finance·Dec 1, 2025
- REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBCYahoo Finance·Nov 28, 2025
- Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBCYahoo Finance·Nov 27, 2025
- Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5Yahoo Finance·Nov 26, 2025
- Quantum BioPharma Ltd. Provides Corporate UpdateYahoo Finance·Oct 31, 2025
- Quantum BioPharma Ltd. Announces Corporate UpdatesYahoo Finance·Oct 30, 2025
- Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of IntoxicationYahoo Finance·Oct 23, 2025
All 21 articles loaded
Price Data
Open$5.17
Previous Close$5.36
Day High$5.54
Day Low$5.17
52 Week High$38.25
52 Week Low$2.07
52-Week Range
$2.07$38.25
$5.28
Fundamentals
Market Cap$31M
P/E Ratio—
EPS$-8.20
Dividend Yield—
Dividend / Share—
ROE-3.5%
Profit Margin—
Debt / Equity—
Trading
Volume208K
Avg Volume (10D)—
Shares Outstanding5.8M
About FSD Pharma Inc - Class B - Class B (Sub Voting)
Quantum BioPharma Ltd. (QNTM) is a forward-thinking biotechnology firm dedicated to creating transformative therapies for challenging medical conditions, with a particular focus on oncology and autoimmune diseases. The company boasts a promising pipeline of innovative biopharmaceuticals, underpinned by advanced technologies and a strong commitment to research and development. Supported by strategic collaborations and an experienced leadership team, Quantum BioPharma is well-positioned to meet the escalating demand for novel therapeutics, making it an attractive proposition for institutional investors navigating the evolving biopharmaceutical sector.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—